Erenumab is under clinical development by Amgen and currently in Phase II for Pain. According to GlobalData, Phase II drugs for Pain have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Erenumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Erenumab overview
Erenumab (Aimovig, Aerinex, Pasurta, Glaseeq) is a human immunoglobulin G2 (IgG2) monoclonal antibody. It is formulated as solution in a single-dose for sub-cutaneous route of administration. Erenumab is indicated for the preventive treatment of migraine in adults.
Erenumab (AMG-334) is under development for the treatment of an episodic migraine and chronic migraine. The drug candidate is administered intravenously or subcutaneously as form an of a solution.
It is under development for rosacea, chronic cluster headache, temporomandibular disorder (TMD) pain, migraine in adults and pediatric patients, persistent headache attributed to mild traumatic brain injury (persistent post-traumatic headache) and trigeminal neuralgia. It was also under development for the treatment of hot flashes associated with menopause and stable angina.
Amgen overview
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines for the treatment of cardiovascular conditions, oncology/hematology, inflammation, bone health, neurological disorders and nephrology conditions. The company analyzes the difficulties of disease and understands the fundamentals of human biology to develop products harnessing advanced human genetics. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has a presence in Asia Pacific, Europe, the Middle East, the Americas and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
For a complete picture of Erenumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
